Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07489066CT.gov Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC | — | Recruiting | — | — | — |
NCT06968195CT.gov Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma | — | Suspended | — | — | — |
NCT07500220CT.gov Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC | — | Recruiting | — | — | — |
NCT07242417CT.gov TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06690281CT.gov A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies | — | Withdrawn | — | — | — |
NCT06902389CT.gov A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06652243CT.gov Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06641453CT.gov CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT06515314CT.gov HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors | — | Recruiting | — | — | — |
NCT05926726CT.gov GPC3-directed CAR-T in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
Show 19 more trialsShow fewer
NCT05120271CT.gov BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04897321CT.gov B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) | — | Recruiting | — | — | — |
NCT06144385CT.gov A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05323201CT.gov Study Of B7H3 CAR-T Cells in Treating Advanced Liver Cancer | — | Recruiting | — | — | — |
NCT05003895CT.gov GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT05028933CT.gov IMC001 for Clinical Research on Advanced Digestive System Malignancies | — | Unknown | — | — | — |
NCT04282044CT.gov Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT04093648CT.gov T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR) | — | Withdrawn | — | — | — |
NCT03884751CT.gov Chimeric Antigen Receptor T Cells Targeting Glypican-3 | — | Completed | — | — | — |
NCT03971747CT.gov AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03980288CT.gov 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 | — | Completed | — | — | — |
NCT02905188CT.gov Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) | — | Completed | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03319459CT.gov FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03302403CT.gov Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | — | Unknown | — | — | — |
NCT03084380CT.gov Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT03146234CT.gov CAR-GPC3 T Cells in Patients With Refractory Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02702960CT.gov Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC) | — | Withdrawn | — | — | — |
NCT01967823CT.gov T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Roswell Park Cancer Institute | P2 | B · 59 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →